{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Deshpande A"],"funding":["Agency for Healthcare Research and Quality","AHRQ HHS"],"pagination":["1314-1322"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7901260"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["72(8)"],"pubmed_abstract":["<h4>Background</h4>For patients at risk for multidrug-resistant organisms, IDSA/ATS guidelines recommend empiric therapy against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas. Following negative cultures, the guidelines recommend antimicrobial de-escalation. We assessed antibiotic de-escalation practices across hospitals and their associations with outcomes in hospitalized patients with pneumonia with negative cultures.<h4>Methods</h4>We included adults admitted with pneumonia in 2010-2015 to 164 US hospitals if they had negative blood and/or respiratory cultures and received both anti-MRSA and antipseudomonal agents other than quinolones. De-escalation was defined as stopping both empiric drugs on day 4 while continuing another antibiotic. Patients were propensity adj"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["De-escalation of Empiric Antibiotics Following Negative Cultures in Hospitalized Patients With Pneumonia: Rates and Outcomes."],"pmcid":["PMC7901260"],"funding_grant_id":["R01 HS024277","R01 HS024277-01A1","K08 HS025026"],"pubmed_authors":["Zilberberg MD","Lindenauer PK","Richter SS","Deshpande A","Haessler S","Higgins T","Rothberg MB","Yu PC","Imrey PB"],"additional_accession":[]},"is_claimable":false,"name":"De-escalation of Empiric Antibiotics Following Negative Cultures in Hospitalized Patients With Pneumonia: Rates and Outcomes.","description":"<h4>Background</h4>For patients at risk for multidrug-resistant organisms, IDSA/ATS guidelines recommend empiric therapy against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas. Following negative cultures, the guidelines recommend antimicrobial de-escalation. We assessed antibiotic de-escalation practices across hospitals and their associations with outcomes in hospitalized patients with pneumonia with negative cultures.<h4>Methods</h4>We included adults admitted with pneumonia in 2010-2015 to 164 US hospitals if they had negative blood and/or respiratory cultures and received both anti-MRSA and antipseudomonal agents other than quinolones. De-escalation was defined as stopping both empiric drugs on day 4 while continuing another antibiotic. Patients were propensity adj","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-04T19:54:32.326Z","creation":"2025-04-04T19:54:32.326Z"},"accession":"S-EPMC7901260","cross_references":{"pubmed":["32129438"],"doi":["10.1093/cid/ciaa212"]}}